NMRK vs REGN · P/E 33, rev $2.74B vs P/E 14, rev $14.34B
Newmark Group Inc (NMRK) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Newmark Group Inc (NMRK) is a real estate services company listed on US.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported NMRK revenue for 2024-12-31 was $2.74B. Net income was $85.5M. Revenue was up 10.9% from 2023-12-31 to 2024-12-31. NMRK currently screens at market cap $3.08B and trailing P/E 33.1.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
NMRK currently screens at market cap $3.08B and trailing P/E 33.1. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the NMRK and REGN stock pages for the full models.
Not investment advice.